-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
NBD-14270
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2411819-82-2.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2411819-82-2 |
| Description | NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100M). |
Product Information
| Synonyms | NBD-14270|CHEMBL4447583|EX-A6397|BDBM50527104|HY-139989|CS-0311379|2411819-82-2|YB7 |
| Molecular Weight | 425.43 |
| Molecular Formula | C18H18F3N5O2S |
| Canonical SMILES | CC1=C(NC(=C1)C2=NC=C(C=C2)C(F)(F)F)C(=O)NC(CN)C3=NC=C(S3)CO |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Yellow to brown (Solid) |
| Storage | 4°C, sealed storage, away from moisture and light * In solvent : -80°C 6 months; -20°C 1 month (sealed storage, away from moisture and light) |
| Complexity | 570 |
| Exact Mass | 425.11333049 |
| In Vitro | NBD-14270 has anti-HIV-1 activity (IC50=0.16 μM ) and Cytotoxicity (CC50=109.3 μM) in single-cycle (TZM-bl Cells) assay. NBD-14270 does not induce toxicity in the U87-CD4-CXCR4 cell line at the doses used for this assay. |
| Target | HIV |
| XLogP3-AA | 1 |
